<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02319239</url>
  </required_header>
  <id_info>
    <org_study_id>ETL R14009</org_study_id>
    <secondary_id>R14009</secondary_id>
    <nct_id>NCT02319239</nct_id>
  </id_info>
  <brief_title>Prostate Cancer Stereotactic Radiotherapy</brief_title>
  <acronym>ESKO</acronym>
  <official_title>Development of Prostate Cancer Stereotactic Radiotherapy in Tampere Using Intra-fractional Movement Detector and Diffusion-weighted Magnetic Resonance Imaging.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tampere University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tampere University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose of the study is to develop a stereotactic radiation treatment to prostate
      cancer which minimizes treatment related toxicity. Movement of the prostate during a
      radiation therapy will be monitored by temporary implanted electromagnetic transmitter. This
      data will be used to define prostate marginals (PTV) for stereotactic treatment. Radiation
      toxicity to rectum will be reduced by using a rectum fixation during a treatment.

      Study group I (20 patients) will be treated 39 x 2 Gy and study group II (20 patients) with
      20 x 3 Gy fractionation schedules. With the data collected from these groups treatment
      marginals to prostate will be defined and used to treat group III (40 patients) with 5 x 7.25
      Gy.

      Second purpose of this study is to assess if Diffusion-weighted magnetic resonance imaging
      could be used to evaluate radiation treatment response in intermediate prostate cancer.
      Androgen deprivation therapy is not allowed in this study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New local prostate cancer patients needing external radiotherapy are included into three
      radiation dose groups;

      Group I will be treated normal dosing (39 x 2 Gy) and study group II with hypofractionated
      dosing (20 x 3 Gy) and group III extreme hypofractionationated dosing. Primary goal is to
      develop safe and effective curative radiotherapy for these patients

      Second aim is to study Diffusion-weighted magnetic resonance image in radiation treatment
      response in intermediate prostate cancer.

      Patients are followed by MRI, PSA, bone scans and quality of life questionaries.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine whether the temporary implanted electromagnetic transmitter could be used to reduce treatment marginals in prostate cancer radiation therapy</measure>
    <time_frame>1 to 3 months</time_frame>
    <description>PSA recurrence</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of DW-MRI to predict the outcome of prostate cancer radiation therapy</measure>
    <time_frame>0 - 12 months</time_frame>
    <description>PSA recurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>1 to 3 months</time_frame>
    <description>quality of life questionaires</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Prostate Neoplasms</condition>
  <condition>Toxicity Due to Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Conventional fractionation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hypofractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic fractionation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Fractionation</intervention_name>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.</description>
    <arm_group_label>Conventional fractionation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionation</intervention_name>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months</description>
    <arm_group_label>hypofractionation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic fractionation</intervention_name>
    <description>During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months</description>
    <arm_group_label>Stereotactic fractionation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Biopsy-proven prostate Cancer

          -  One or two risk factors for intermediate prostate cancer:

               -  Gleason score 7

               -  T2b-T2c

               -  PSA 10-20 microg/l

          -  No need for androgen deprivation therapy

          -  Eligible fo MRI

          -  Radical radiotherapy

        Exclusion Criteria:

          -  Locally advanced or metastatic prostate cancer

          -  Previous RT to pelvic reason

          -  Other severe disease

          -  Previous cancer within 5 years

          -  Severe urinary symptoms at the start of the study (I-PSS over 20)

          -  Wide cavity after TURP
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petri Reinikainen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tampere Unviersity Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pirkko-Liisa Kellokumpu-Lehtinen, MD,PhD</last_name>
    <phone>+358331163227</phone>
    <email>pirkko-liisa.kellokumpu-lehtinen@pshp.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <zip>33521</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pirkko-Liisa Kellokumpu-Lehtinen</last_name>
      <email>klpike@uta.fi</email>
    </contact>
    <investigator>
      <last_name>Petri Reinikainen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2014</study_first_posted>
  <last_update_submitted>December 18, 2014</last_update_submitted>
  <last_update_submitted_qc>December 18, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate neoplasms</keyword>
  <keyword>Urogenital neoplasms</keyword>
  <keyword>Genital neoplasms, male</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>PSA</keyword>
  <keyword>DW-MRI, diffusion weighted MRI</keyword>
  <keyword>Intra-fractional movement</keyword>
  <keyword>Hypofractionated radiotherapy</keyword>
  <keyword>Stereotactic</keyword>
  <keyword>Toxicity due to radiotherapy</keyword>
  <keyword>Quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

